PDCD1 and neoplasm: For example, monoclonal antibodies (mAbs) targeting PD-1 or PD-L1 demonstrate capacity to improve the functional state of tumor-infiltrating lymphocytes, reinvigorating their inherent capacity to identify and eliminate cancer cells [93].